- ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
- ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors
- REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
- Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
- Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer or HR Positive, HER2 Negative Breast Cancer
- Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer
More ▼
Key statistics
As of last trade Daiichi Sankyo Co Ltd (4568:TYO) traded at 5,402.00, -2.14% below its 52-week high of 5,520.00, set on May 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5,366.00 |
---|---|
High | 5,448.00 |
Low | 5,358.00 |
Bid | 5,401.00 |
Offer | 5,403.00 |
Previous close | 5,385.00 |
Average volume | 5.93m |
---|---|
Shares outstanding | 1.95bn |
Free float | 1.92bn |
P/E (TTM) | 52.58 |
Market cap | 10.71tn JPY |
EPS (TTM) | 104.63 JPY |
Annual div (ADY) | 50.00 JPY |
---|---|
Annual div yield (ADY) | 0.93% |
Div ex-date | Mar 28 2024 |
Div pay-date | Jun 18 2024 |
Data delayed at least 20 minutes, as of May 13 2024 01:37 BST.
More ▼